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Abstract
OBJECTIVE: To investigate the correlativity be-
tween the changes of blood measures related to
blood stasis blocking collaterals and gene expres-
sion levels of angiotensin-converting enzyme (ACE)
and ACE2 ofrenal cortex in diabetic rats with stasis
blocking collaterals syndrome, as well as the effec-
tof stasis removing and collaterals dredging.
METHODS: Male Sprague-Dawley rats were divid-
ed randomly into normal control group (C group),
high-carbohydrate-fat control group (H group) and
streptozotocin (STZ)-injecting group. The diabeti-
crats were induced from rats in the STZ-injecting
groupby high-carbohydrate-fat diet combined
with STZ intraperitoneal injection, with sustained
high-carbohydrate-fat diet fed afterwards, and
were further divided into model group (M group)
and Chinese medicine of stasis removing and collat-
erals dredging group (Z group). Rats in the Z group
were fed with stasis-removing-and-collater-
als-dredging herbal granule suspension intragastri-
cally daily for 16 weeks, while drinking water of cor-
responding volume was administrated to the rats
in other groups. At the end of the 16th week after
successful establishment of models, the ultrastruc-
tures of glomeruli in different groups were detect-
ed by a transmission electron microscopy; and
blood measures related to blood stasis blocking
collaterals, including lipid profile and blood viscosi-
ty measures, were tested, as well as the relative
gene expressions of ACE and ACE2.
RESULTS: Changes in ultrastructures of glomeruli
in the M group were characterized by lack of clarity
in structure and occasional thickening of glomeru-
lar basement membrane and extensive fusion in
foot processes. The correlation analysis showed
that there were positive correlations between lipid
profile, blood viscosity, and the ACE mRNA expres-
sion levels in the M group (P<0.05), except for cho-
lesterol. And except for triglyceride, the blood mea-
sures were in negative correlation with the ACE2
mRNA expression levels in the M group (P<0.05).
Compared with the C and H groups, the lipid pro-
file, plasma viscosity and blood viscosity were sig-
nificantly higher (P<0.01). All the above-mentioned
measures were significantly improved in the Z
group rats (P<0.05). ACE mRNA expression was sig-
nificantly higher in the M group thanin the C group
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(P<0.05). ACE2 mRNA level was significantly lower
in the M group than in the C and H groups (P<0.01);
and its levelin the Z group was higher than that in
the M group (P<0.01).
CONCLUSION: Blood measuresrelated to blood sta-
sis blocking collaterals had positive linear correla-
tions with ACE mRNAexpression and negative lin-
ear correlations with ACE2 mRNA expression in the
M group. Chinese recipe of stasis removing and col-
laterals dredging could play a renal protecting role
for diabetic rats by reducing lipid profile and blood
viscosity, down-regulating ACE mRNA expression
and up-regulating ACE2 mRNA expression.
© 2014 JTCM. All rights reserved.
Key words: Diabetic nephropathies; Removing
blood stasis and dredging collaterals; Streptozoto-
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INTRODUCTION
Diabetes mellitus (DM) is posing a direct health threat
to humans. A study estimating the world prevalence of
diabetes reported that, the prevalence would be 6.4%in
2010 and would have increase to 7.7% by 2030, which
indicated a growing burden of DM worldwide.1 As one
of the primary complications of DM, diabetic nephrop-
athy (DN) is also the major cause of end-stage renal
disease (ESRD). Therefore, it is significantly meaning-
ful to prevent or delay the deterioration of renal func-
tion in patients with DM. Viewed from the modern
medicine, activation of reninangiotensin system (RAS)
is believed to be the main factor involved in the patho-
genesis of DN. Blockers of the RAS, angiotensin con-
verting enzyme inhibitor (ACEI) or angiotensin recep-
tor blocker (ARB), might protect against the progres-
sion of nephropathy due to DM.2,3 And they have been
generally accepted to be the first-line drugs for protect-
ing kidney.4
From a different perspective, DN is diagnosed and
treated based on syndrome differentiation in Chinese
medicine. In addition to the pathogenesis of Qi and
Yin vacuity of DM, DN has another primary pathogen-
esis, which is blood stasis blocking collaterals of kidney.
And this has become a common view in the Chinese
medicine field.5-8 That applying Chinese medicine of
activating blood and removing stasis to clinical DN has
appeared effective.9
However, the problem is whether the pathogenesis of
blood stasis blocking collaterals has something to do
with the dysfunction of RAS in the occurrence and de-
velopment of DN. Moreover, it is unclear whether the
Chinese recipe of stasis removing and collaterals dredg-
ing could target some components in RAS as acting
points to play a renal protecting role. To answer these
questions, we tested the blood measures related to
blood stasis blocking collaterals, including lipid profile
and blood viscosity measures, as well as the relative
gene expression levels of two key enzymes in the RAS,
ACE and ACE2, and explored the internal correlations
among them.
MATERIALS ANDMETHODS
Animals and experimental protocol
Fifty healthy male Sprague-Dawley rats, four-week-
old, weighing (90±10) g, were purchased from the Lab-
oratory Animal Center of Hebei Province (Shijia-
zhuang, China, certificate of quality No. SCXK Hebei
2008-1-003). The rats were housed in a tempera-
ture-and-humidity-controlled environment (22℃-
24℃, 50%-60%) on a normal 12h light-dark cycle. All
rats were free access to food and water. All experimen-
tal procedures were approved by the Ethics Committee
of Hebei Medical University (No. DW2013001), Chi-
na, and were performed under Guidance Suggestions
for the Care and Use of Laboratory Animals published
by the Ministry of Science and Technology of the Peo-
ple's Republic of China.
After adaptive feeding for 1 week, rats were divided in-
tonormal control group (C group, n=10), high-carbo-
hydrate-fat control group (H group, n=10) and
STZ-injecting group (n=30) by random number table
method. Rats in the C group fed with standard ra-
tchow (3.51 kcal/g), while other rats were maintained
on high-carbohydrate-fatdiet (4.43 kcal/g) for 4 consec-
utiveweeks. Then rats in streptozotocin (STZ)-inject-
ing group were intraperitoneally injected with STZ
40 mg/kg (diluted with 0.1 M pH 4.3 sodium citrate
solution to 1% ), and the injectionmust be finished
within 30 min. Meanwhile, rats in the C and H groups
were injected corresponding volume of sodiumcitrate
solution. Seventy-two hours later, the diabeticrats were
identified by testing the levels of the random blood glu-
cose (RBG) with sample from their tail veins. It was
considered as a successful model if RBG of the rat was
higher than 16.7 mmol/L. Unsuccessful models were
rejected. A total of 25 up-to-standard rats in the
STZ-injecting group were divided further into model
group (M group, n=12) and stasis-removing-and-collat-
erals-dredging herbs group (Z group, n=13) randomly.
All rats were maintained on previous diet for the fol-
lowing 16 weeks. Meanwhile, rats in the Z group were
fed with stasis-removing-and-collaterals- dredging herb-
al granule suspensionintragastricallyat a dose of 1.08 g/
kg once daily. The dose was converted according to hu-
man usual dose, compatibility proportion and the
body type coefficient of rat to human.10 Drinking wa-
ter of corresponding volume was intragastrically admin-
istrated daily to the rats in the C, H and M groups.
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During the study, no other intervene was given. Rats
were sacrificed 16 weeks after induction of diabetes.
Medicine and reagents
Stasis-removing-and-collaterals-dredging herbal granu-
leprescription consist of Danshen (Radix Salviae Milt-
iorrhizae), Chuanxiong (Rhizoma Chuanxiong), Dilong
(Pheretima Aspergillum), Shuizhi (Hirudo), Quanxie
(Scorpio), were donated by Guangdong Yifang Pharma-
ceutical Co., Ltd. (Fuoshan, China) (Table 1). Gran-
ules were mixed at the ratio of 27∶26∶10∶30∶20 by
the above order.
Standard ratchow and high-carbohydrate-fatdiet (car-
bohydrate 44%, fat 22.3%, protein18.6%, water 10%,
aswell as minerals and vitamins) were produced by the
Laboratory Animal Center of Hebei (Shijiazhuang,
China). Streptozotocin (STZ, Lot. L27453) was pur-
chased from Enzo Life Science Co., Ltd. (Farmingdale,
NY, USA), Triquick Reagent Kit (Lot. No. 20130530)
from Solarbio Science & Technology Co., Ltd. (Bei-
jing, China), In vitro gen M-MLV First Strand Kit
(Lot. No. 8213068), Ribonuclease Inhibitor (Lot. No.
8213025), and Platinum SYBR Green qPCR Super-
Mix-UDG (Lot. No. 8213021) from Life Technologies
Corporation (Carlsbad, CA, USA).
Electron microscopic examination
At sacrifice, kidneys were excised, the right one was
weighed, cortical tissue was divided into 1mm×1mm×
1mm in size, and some were fixed using phosphate buf-
fer (PBS, 0.2 M) from Solarbio Science & Technology
Co., Ltd. (Beijing, China), containing 4% glutaralde-
hydeand 1% osmium tetroxide, washed by PBS (0.1 M),
dehydrated using graded acetone, and then infiltrated
and embedded using the mixture of acetone and epoxy
resin. After slicing and staining, the ultrastructures of
glomeruli were detectedby Hitachi H-7650 transmis-
sion electron microscopy (Hitachi Ltd., Tokyo, Japan).
Collection and test of blood samples
At the time of sacrifice, blood was collected from the
abdominal aorta. Serum lipid profile were determined
by a Hitachi automatic biochemical analyzer (7170, Hi-
tachi, Tokyo, Japan). And blood viscosity measures
were tested by an automatic blood rheological analysis
system (ZL 9000 plus, Zhong Chi Wei Ye Science and
Technology Co., Ltd., Beijing, China).
Real-time fluorescence quantitative polymerase
chain reaction (PCR)
Some kidney cortex was cryopreserved at ﹣ 80℃ for
examination by real-time PCR. When examined, total
RNA was extracted from the renal cortex using-
Triquick Reagent. Then, the cDNA was reverse-tran-
scribed from the total RNA using M-MLV First Strand
Kit according to the manufacture's instructions. Prim-
ers were synthesized at Sangon Biotech Co., Ltd.
(Shanghai, China) (Table 2). Real-time quantitative
RT-PCR was performed using Platinum SYBR Green
qPCR Super Mix-UDG and Eco Real-Time PCR Sys-
tem (Illumina, San Diego, CA, USA). The expression-
of mRNA was corrected by β-actin.
Statistical analysis
All data were expressed as mean ± standard deviation
( xˉ ± s) and analyzed using Statistics Product and Ser-
vice Solutions 17.0 software (SPSS v.17.0 for windows;
SPSS Inc., Chicago, IL, USA). Statistical significance-
was evaluated using ANOVA process to identify com-
parisonamong different groups. Correlativity of blood
measures and ACE, ACE2 mRNA expressionlevels in
M group covariates was analyzed with linear correla-
tion. P<0.05 was regarded as asignificant difference.
RESULTS
Ultrastructural changes in glomeruli under
electronmicroscope
In the C group, glomerular basement membrane
(GBM) had a clear structure, with smooth and unifor-
mthickness, while foot processes were in alignment and
without fusion. The renal cortex in the H group also
showed basic normal ultrastructure. However, lack of
clarity characterised the structure of GBM in the M
group, as well as occasional thickening of GBM. And
foot processes showed extensive fusion. By contrast,
changes in the ultrastructureof glomeruli were reversed
to a certain extent in the Z group. The structure of
GBM was clear; and foot processes showed segmental
fusion (Figure 1).
Correlation between blood measures and relative
expression of ACE and ACE2 mRNA in M group
The results from analysis showed that, there were posi-
tive correlations between the blood measures, lipid pro-
file and blood viscosity, and the ACE mRNA expres-
sion levels in the M group (P<0.01 or P<0.05), except
for cholesterol (P>0.05). And except for triglyceride (P>
0.05), the blood measures and the ACE2 mRNA ex-
pression levels in the M group were in negative correla-
tion (P<0.01 or P<0.05) (Table 3).
Lipid profile and blood viscosity
Total cholesterol, triglyceride, low density lipoprotein
and plasma viscosity in the M group were significantly
higher than that in the C and H groups (P<0. 01), as
well as whole blood viscosity under shear rates of 30s-1
and 200s-1 (P<0. 05). Compared with the M group, the
Z group intervened with Chinese recipe of Chinese rec-
ipe of stasis removing and collaterals dredging, showed
a significant reduction in triglyceride, low density lipo-
protein, plasma viscosity and whole blood viscosity un-
der shear rates of 200s-1 (P<0.01), as well as in choles-
terol and whole blood viscosity under shear rates of
30s-1 (P<0. 05). In addition, the differences between C
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and H groups in cholesterol and low density lipopro-
tein were significant (P<0.01) (Table 4).
Gene expression levels of ACE and ACE2 mRNA
ACE mRNA expression level in renal cortical tissue
Blood measure
Cholesterol
Triglyceride
Low density lipoprotein
Plasma viscosity
Whole blood viscosity-shear rate 1S-1
Whole blood viscosity-shear rate 5S-1
Whole blood viscosity-shear rate 30S-1
Whole blood viscosity-shear rate 200S-1
ACE mRNA
r
0.770
0.967
0.928
0.915
0.877
0.908
0.814
0.816
P value
0.073
0.000
0.003
0.004
0.010
0.005
0.026
0.025
ACE2 mRNA
r
0.948
0.787
0.835
0.965
0.938
0.957
0.939
0.976
P value
0.004
0.063
0.038
0.002
0.006
0.003
0.005
0.001
Table 3 Analysis on correlation between blood measures and relative expression of ACE and ACE2 mRNA of renal cortex in the
model group
Notes: model group was exposed to diabetes mellitus by high-carbohydrate-fatdietand intraperitoneal injection of streptozotocin, with no
subsequent treatment. ACE: angiotensin-converting enzyme.
Figure 1 Ultrastructural changes in glomeruli under the electron microscope (×20000)
A: C group; B: H group; C: M group; D: Z group. C group: normal control group, used as controls; H group: high-carbohydrate-fat
control group, fed with high-carbohydrate-fat diet; M group: model group, exposed to diabetes mellitus (DM) by high-carbohy-
drate-fatdietand intraperitonealinjection of streptozotocin, with no subsequent treatment; Z group: Chinese medicine of stasis re-
moving and collaterals dredging group, exposed to DM and then administration of Chinese medicine of stasis removing and col-
laterals dredging herbal granule suspension intragastrically.
A B C D
Granule name
Danshen (Radix Salviae Miltiorrhizae)
Chuanxiong (Rhizoma Chuanxiong)
Dilong (Pheretima Aspergillum)
Shuizhi (Hirudo)
Quanxie (Scorpio)
Lot. number
1107057
1108827
1105024
1106113
1107253
Packing size (g/package)
1.8
1.3
1.0
1.5
1.0
Equivalent to crude drug (g)
10
6
10
3
3
Table 1 Format of Chinese herbal granules applied in the study
Gene
β-actin
ACE
ACE2
Sequence of primers (5'→3')
(S) ACCCGCGAGTACAACCTTCT
(AS) TTCAGGGTCAGGATGCCTCT
(S) TCCTATTCCCGCTCATCT
(AS) CCAGCCCTTCTGTACCATT
(S)ATGAAGAGTATGTGGTCCTG
(AS) TGGTTTCGGTTGTAGTTG
Length of product (bp)
266
127
124
Annealing temperature (℃)
60
60
60
Table 2 Primers for rat genes used in real-time PCR
Notes: PCR: polymerase chain reaction; ACE: angiotensin-converting enzyme.
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was significantly higher in the M group thanin the C
group (P<0.05). Compared with the M group, ACE
mRNA expression level in the Z group had tendency
of reduction, but it was not statistically significant.
ACE2 mRNA expression level was significantly lower
in the M group thanthat in the C and H groups (P<
0.01). Meanwhile, its level in the Z groupwas higher
than that in the M group, and the difference was statis-
tically significant (P<0.01) (Table 5).
DISCUSSION
In Chinese medicine, DN is characterized by enduring
illness entering collaterals, stagnation of Qi and blood
blocking renal collaterals. Clinical researches showed
that, blood-stasis syndrome penetrated the whole pro-
cess of DN,11 and blood-stasis syndrome might be the
cause of urine protein increase of DN patients.12 By the
quantitativecorrelation analysis studies between clinical
manifestation and hemodynamic measures of patients
with blood-stasis syndrome, Academician Keji Chen
put forward the quantitative diagnosis standard for
blood-stasis syndrome. The whole blood viscosity, ex-
traneous thrombosis, platelet aggregation and thrombe-
lastogram made the greatest contribution to blood-sta-
sis syndrome; and some patients had elevated hemoglo-
bin, blood viscosity, total cholesterol and triglyceride.13,14
A clinical research reported that, all the DN patients
with different syndromes had manifestation of
blood-stasis syndrome along with dyslipidemia and ab-
errant hemorrheology.15 Therefore, lipid profile and he-
modynamic measures could be regarded to be related
to blood-stasis syndrome.
In modern medicine, RAS attracts much attention in
terms of DN. In RAS, angiotensin Ⅱ (Ang Ⅱ) is a
mainactive peptide, which acts on several targetorgans,
includingkidney, andinfluences blood pressure, fluid
and electrolyte balance, electrolyte homeostasis and so
on.16 Within the kidney, ACE and ACE2, are two en-
zymes which have similar distributions, in distal and
proximal tubules, and to a much lesser extent in glom-
eruli, as assessed by both gene and protein expres-
sion.17-19 ACEfunctions primarily as a "peptidyl dipepti-
dase" in the RAS, turning AngⅠ to AngⅡ by remov-
ing dipeptides from the C terminus of peptide sub-
strates.20 By contrast, ACE2, a homologue of ACE,
cleaves only a single amino acid from the C terminus
of any given substrate, such as AngⅠ, AngⅡ and ape-
lin.21 Therefore it dissevers the C-terminal amino acid
from AngⅠ to make angiotensin-(1-9),22 which is fur-
ther converted into Ang-(1-7) by ACE or other pepti-
dases.23 And ACE2 also directly converts Ang Ⅱ to
Ang-(1-7).23,24 The role of Ang-(1-7) remains controver-
sial, but in most animal studies it has been believed to
play a role of promoting vasodilatation, apoptosis, and
growth arrest.25,26 In addition, Ang-(1-7) could also
Blood measure
n
Cholesterol (mmol/L)
Triglyceride (mmol/L)
Low density lipoprotein (mmol/L)
Plasma viscosity (mPa.s)
Whole blood viscosity-shear rate 1s-1 (mPa.s)
Whole blood viscosity-shear rate 5s-1 (mPa.s)
Whole blood viscosity-shear rate 30s-1 (mPa.s)
Whole blood viscosity-shear rate 200s-1 (mPa.s)
C group
10
1.44±0.19
0.70±0.31
0.40±0.09
0.93±0.45
20.43±2.73
8.88±1.44
5.07±1.11
3.56±0.73
H group
10
2.10±0.50a
0.81±0.21
0.75±0.25a
1.10±0.37
25.27±1.91ab
11.12±1.04ab
5.13±0.36
3.70±0.28
M group
8
19.10±2.12ac
2.91±1.48ac
12.28±1.28ac
2.06±0.34ac
22.62±2.21
9.43±0.73
6.13±0.49ac
4.50±0.36ac
Z group
8
13.63±5.35ace
1.34±0.63bdf
7.06±3.49acf
1.55±0.22acf
23.43±1.96bd
10.29±0.85ac
5.63±0.39bde
4.07±0.26bdf
Table 4 Comparison of blood measures of rats in different groups ( xˉ ±s)
Notes: C group: normal control group, used as controls; H group: high-carbohydrate-fat control group, fed with high-carbohydrate-fatdi-
et; M group: model group, exposed to diabetes mellitus (DM) by high-carbohydrate-fatdietand intraperitoneal injection of streptozotocin,
with no subsequent treatment; Z group: Chinese medicine of stasis removing and collaterals dredging group, exposed to DM and then ad-
ministration of Chinese medicine of stasis removing and collaterals dredgingherbal granule suspensionintragastrically. Compared with C
group, aP<0.01, dP<0.05; compared with H group, bP<0.05, cP<0.01; compared with M group, eP<0.05, fP<0.01.
Group
C
H
M
Z
ACE mRNA
1.00±0.00
1.23±0.39
1.72±0.75a
1.54±0.30
ACE2 mRNA
1.00±0.00
1.09±0.15
0.39±0.05bc
0.69±0.07ade
Notes: C group: normal control group, used as controls; H
group: high-carbohydrate-fat control group, fed with high-carbo-
hydrate-fatdiet; M group: model group, exposed to diabetes mel-
litus (DM) by high-carbohydrate-fatdietand intraperitoneal in-
jection of streptozotocin, with no subsequent treatment; Z
group: Chinese medicine of stasis removing and collaterals
dredging group, exposed to DM and then administration of Chi-
nese medicine of stasis removing and collaterals dredgingherbal
granule suspensionintragastrically. ACE: angiotensin-converting
enzyme; PCR: polymerase chain reaction. Compared with C
group, aP<0.05, bP<0.01; compared with H group, cP<0.01, dP<
0.05; compared with M group, eP<0.01.
Table 5 The relative gene expression levels of ACE and ACE2
of renal cortex in different groups by real-time PCR [2-ΔΔCt,
( xˉ ±s)]
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ameliorate insulin resistance.27 Therefore, although
ACE and ACE2 are not the only enzymes involved in
the RAS pathway, levels of Ang Ⅱ could be regulated
by the opposing action of ACE and ACE2. As a result,
the levels of ACE and ACE2 could influence RAS obvi-
ously. ACE determines both the production of Ang Ⅱ
and the degradation of Ang-(1-7) either by stimulating
an alternative pathway for AngⅠ degradation orby fa-
cilitating the degradation of Ang Ⅱ into Ang-(1-7).
However, ACE2 can regulate the levelof Ang Ⅱ by fa-
cilitating the conversion of Ang Ⅱ into Ang-(1-7),28
and works as a potential therapy for diabetic nephropa-
thy by enhancing the degradation of Ang Ⅱ.29 A study
on mice at an early stage of diabetes exhibit increased
ACE2 protein in renal cortical tubules coupled with
profound reduction in renal expression of ACE,18
which means protection for thekidneys in the early
phases of diabetes by limiting the renal accumulation
of Ang Ⅱ and favoring Ang-(1-7) formation. Howev-
er, decreased ACE2 expression in concert with in-
creased ACE activity may fosterkidney damage in dia-
betes.17 ACE2 truly seems to be the "good" ACE, hav-
ing beneficial effects on the kidney.30 Meanwhile, RAS
blockade was reported to up-regulate renal protein ex-
pression of ACE2.31-33
In this study, DM had been proved to be the direct
cause of the abnormal ultrastructure of glomeruli in
the M group rats, compared with the C and H groups.
Blood stasis related measures, including lipid profile
and blood viscosity, increased in the M group rats, sug-
gesting that the blood was in high viscosity, which was
the unification of microcirculation disturbance in renal
diseases from modern medicine and blood stasis block-
ing collaterals from Chinese medicine. Real-time PCR
examination showed up-regulation of ACE-mRNA ex-
pression and down-regulation of ACE2-mRNA expres-
sion in the M group at the end of 16th week after es-
tablishing DM models, compared with the C group.
Linear correlation analysis suggested that, majority of
blood stasis related measures were in positive correla-
tions with ACE mRNA expression level, and in nega-
tive correlation with ACE2 mRNA expression level in
the M group rats. The Chinese recipe of stasis remov-
ing and collaterals dredging intervention improved the
ultrastructure of glomeruli, reduced the lipid profile
and blood viscosity, partly reversed the down-regula-
tion of ACE2-mRNA expression of DM rats, but did
not influence the ACE mRNA expression significantly.
Above results suggested that, pathogenesis of blood sta-
sis blocking collaterals had something to do with the
dysfunction of RAS, and Chinese medicine of stasis re-
moving and collaterals dredging could play a renal pro-
tecting role by exerting influence on ACE2 in RAS.
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